ALEMBIC PHARMACEUTICALS LTD. - 533573 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Malika Chirayu Amin Alembic Pharmaceuticals Ltd - 533573 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pranav Chirayu Amin ALEMBIC PHARMACEUTICALS LTD. - 533573 - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pranav Chirayu Amin Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificates published by the Company on behalf of the shareholder(s) and / or legal heir(s) of the registered shareholder(s) in English language newspaper - Business Standard on 1st January, 2020. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the registered shareholder(s) and / or legal heir(s) of the registered shareholders on 30th December, 2019 as mentioned in the attached letter. Alembic Pharmaceuticals Ltd - 533573 - Closure of Trading Window
With reference to the captioned matter, this is to inform the exchange that in terms of the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company will remain closed from 1st January, 2020 till 48 hours after the declaration of the unaudited financial results for the quarter and nine months period ended 31st December, 2019. The date of the Board Meeting for considering the unaudited financial results for the quarter and nine months period ended 31st December, 2019, will be intimated in due course. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pranav Chirayu Amin USFDA nod may boost Alembic Pharma
Shares of Alembic Pharmaceuticals will remain in focus, as the company on Tuesday said it has received final approval from the US Food & Drug Admi ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Travoprost Ophthalmic Solution USP, 0.004%. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the legal heir(s) of the registered shareholder(s) of such lost share certificate(s) have requested the Company for issue of duplicate share certificate(s) for the purpose of claiming those shares from the Investor Education and Protection Fund (IEPF).